AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3533025 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated nebulization of Salbutamol at 37 degrees C
Number of subjects: 40
Study 3533025 — intervention group
Group type: COMPARATOR
Intervention: Standard nebulization of Salbutamol
Number of subjects: 40
Study 28045553 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental training
Number of subjects: 28
Study 28045553 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control)
Number of subjects: 28
Study 26823602 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line bevacizumab-based therapy
Number of subjects: 181
Study 22496207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (4 days treatment, n = 5)
Number of subjects: 53
Study 22496207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment, n = 5)
Number of subjects: 53
Study 22496207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (long-term treatment)
Number of subjects: 53
Study 22496207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (long-term treatment)
Number of subjects: 53
Study 20551726 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web‐based training (COPE: Collaborative Opioid Prescribing Education)
Number of subjects: 213
Study 20551726 — intervention group
Group type: COMPARATOR
Intervention: Both groups (web training and control)
Number of subjects: 213
Study 19085342 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 32 mg
Number of subjects: 1975
Study 19085342 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-HCT 32/12.5 mg
Number of subjects: 1975
Study 19085342 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-HCT 32/25 mg
Number of subjects: 1975
Study 15844675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 165
Study 15844675 — intervention group
Group type: COMPARATOR
Intervention: Self-help information package (Control)
Number of subjects: 165
Study 11919438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 0
Study 11919438 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study 10357049 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg)
Number of subjects: 238
Study 10357049 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 238
Study 8733702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol for mucositis prophylaxis
Number of subjects: 15
Study 8733702 — intervention group
Group type: COMPARATOR
Intervention: Placebo for mucositis prophylaxis
Number of subjects: 15
Study 8733702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 15
Study 8733702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1656517 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/day omega-3-PUFA
Number of subjects: 26
Study 1656517 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g/day omega-3-PUFA
Number of subjects: 26
Study 1656517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7044407 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG report available to clinician
Number of subjects: 300
Study 7044407 — intervention group
Group type: COMPARATOR
Intervention: CTG report withheld from clinician
Number of subjects: 300
Study 31490536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulphate plus aspirin (600 mg on day 1, then 75 mg per day through day 90; plus 50 to 325 mg of aspirin per day)
Number of subjects: 4881
Study 31490536 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (same range of dosages as clopidogrel)
Number of subjects: 4881
Study 31490536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel bisulphate plus aspirin
Number of subjects: 4881
Study 31490536 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 4881
Study 25311333 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-arm trial intervention including a one-time, half-day educational session with targeted sexual health education, body awareness and relaxation training, and mindfulness-based cognitive therapy strategies, followed by two sessions of tailored telephone counseling.
Number of subjects: 37
Study 23843526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis applied to fMRI data
Number of subjects: 0
Study 21696078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistulotomy with marsupialization
Number of subjects: 50
Study 21696078 — intervention group
Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 50
Study 20178283 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 25%
Number of subjects: 120
Study 20178283 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 50%
Number of subjects: 120
Study 20178283 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 75%
Number of subjects: 120
Study 20178283 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results frequency at 100%
Number of subjects: 120
Study 20178283 — intervention group
Group type: EXPERIMENTAL
Intervention: Task complexity (simple and complex)
Number of subjects: 120
Study 15969777 — intervention group
Group type: COMPARATOR
Intervention: didanosine (ddI)
Number of subjects: 116
Study 15969777 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine (ddI) + stavudine (d4T)
Number of subjects: 116
Study 15969777 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine (d4T)
Number of subjects: 116
Study 12462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine secretin infusions
Number of subjects: 0
Study 12462350 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human secretin infusions
Number of subjects: 0
Study 12462350 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 0
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin stimulation
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical ultrasound
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical neovagina construction
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dilators
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal response to gonadotrophin stimulation
Number of subjects: 12
Study 10325257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcome
Number of subjects: 12
Study 9199740 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-507
Number of subjects: 20
Study 9199740 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (as add-on therapy)
Number of subjects: 20
Study 9199740 — intervention group
Group type: COMPARATOR
Intervention: Timolol and Betaxolol (as control)
Number of subjects: 20
Study 1756844 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1.6 mg daily)
Number of subjects: 35
Study 1756844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6961762 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg i.v. over 5 min
Number of subjects: 5
Study 6961762 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg orally
Number of subjects: 5
Study 6961762 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg orally
Number of subjects: 5
Study 30523432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education intervention focusing on gut microbiota composition
Number of subjects: 44
Study 30523432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 29145894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of myo‐inositol twice daily for 12 months
Number of subjects: 164
Study 29145894 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo twice daily for 12 months
Number of subjects: 164
Study 25537234 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (group sessions and educational material)
Number of subjects: 7498
Study 24276074 — intervention group
Group type: EXPERIMENTAL
Intervention: AboBTXA
Number of subjects: 54
Study 24276074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 23084759 — intervention group
Group type: COMPARATOR
Intervention: Control (C) treatment with 150g/d of diet
Number of subjects: 40
Study 23084759 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate restriction (M) with 105g/d of diet
Number of subjects: 40
Study 23084759 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe restriction (S) with 75g/d of diet
Number of subjects: 40
Study 23084759 — intervention group
Group type: EXPERIMENTAL
Intervention: Refed moderate restriction (MF)
Number of subjects: 40
Study 23084759 — intervention group
Group type: EXPERIMENTAL
Intervention: Refed severe restriction (SF)
Number of subjects: 40
Study 20027431 — intervention group
Group type: COMPARATOR
Intervention: Dry heat sterilization (G1)
Number of subjects: 60
Study 20027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclave sterilization (G2)
Number of subjects: 60
Study 20027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave irradiation (G3)
Number of subjects: 60
Study 20027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde sterilization (G4)
Number of subjects: 60
Study 20027431 — intervention group
Group type: COMPARATOR
Intervention: Control (no sterilization) (G5)
Number of subjects: 60
Study 17238884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block (Group B) with 1 ml 0.25% bupivacaine and 2 ml i.v. saline as control
Number of subjects: 82
Study 17238884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve block (Group B)
Number of subjects: 82
Study 15960852 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing of blood glucose group; interpreted with nurse-practitioner to inform adjustment of medication
Number of subjects: 450
Study 15960852 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose group with personal use of results
Number of subjects: 450
Study 15960852 — intervention group
Group type: COMPARATOR
Intervention: Control group with three monthly HbA1c measurements; interpreted with nurse-practitioner
Number of subjects: 450
Study 12324991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 3577
Study 12324991 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 3577
Study 12324991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study 9818639 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 499
Study 9818639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low potency neuroleptics
Number of subjects: 499
Study 9818639 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate potency neuroleptics
Number of subjects: 499
Study 9818639 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-high potency neuroleptics
Number of subjects: 499
Study 9818639 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency neuroleptics
Number of subjects: 499
Study 8631403 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge with the axillary drain in situ (n = 39)
Number of subjects: 101
Study 8631403 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those not opting for early discharge)
Number of subjects: 101
Study 2560283 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril for four weeks
Number of subjects: 0
Study 2560283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2560283 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (as a reference)
Number of subjects: 0
Study 858019 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeroradiography
Number of subjects: 40
Study 858019 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 40
Study 30516096 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consultations with a spiritual counselor
Number of subjects: 153
Study 30516096 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 153
Study 30516096 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning/Peace experience
Number of subjects: 153
Study 28234565 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 10
Study 28234565 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 10
Study 26436470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 0
Study 26436470 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 0
Study 26436470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 26436470 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors (general)
Number of subjects: 0
Study 26436470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23599357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with olive oil
Number of subjects: 4449
Study 23599357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 4449
Study 23599357 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 4449
Study 22115228 — intervention group
Group type: EXPERIMENTAL
Intervention: LeGoo (LG)
Number of subjects: 110
Study 22115228 — intervention group
Group type: COMPARATOR
Intervention: Conventional vessel loops (VL)
Number of subjects: 110
Study 19451668 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-sand walking (n = 19)
Number of subjects: 38
Study 19451668 — intervention group
Group type: COMPARATOR
Intervention: Firm-surface walking (n = 19)
Number of subjects: 38
Study 15960695 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention (e-mail reminders)
Number of subjects: 628
Study 15960695 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented intervention (e-mail reminders + additional resources)
Number of subjects: 628
Study 15960695 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 628
Study 12196361 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week VNCOP-B plus G-CSF regimen
Number of subjects: 306
Study 12196361 — intervention group
Group type: COMPARATOR
Intervention: 12-week VNCOP-B plus G-CSF regimen
Number of subjects: 306
Study 9465841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus and cyclosporine administered concomitantly (schedule I)
Number of subjects: 24
Study 9465841 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus administered 4 hours after cyclosporine (schedule II)
Number of subjects: 24
Study 7617182 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 million international units (MIU) of interferon beta-1b (IFNB)
Number of subjects: 372
Study 7617182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 million international units (MIU) of interferon beta-1b (IFNB)
Number of subjects: 372
Study 7617182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 2649124 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 0.07 mg kg‐1 i.v. (9 patients)
Number of subjects: 29
Study 2649124 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 1 mg kg‐1 by mouth (11 patients)
Number of subjects: 29
Study 2649124 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 29
Study 2649124 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (11 patients)
Number of subjects: 29
Study 406628 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 10
Study 406628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28880419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care programme
Number of subjects: 0
Study 28880419 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study 26927900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside
Number of subjects: 350
Study 26927900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside infusion
Number of subjects: 350
Study 26927900 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulfate
Number of subjects: 350
Study 26927900 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside infusion
Number of subjects: 350
Study 26927900 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside bolus injection
Number of subjects: 350
Study 24117857 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention by practice nurses
Number of subjects: 330
Study 24117857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motivational interviewing)
Number of subjects: 330
Study 21947813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (4, 8, or 12 kcal/kg/week) for 6 months
Number of subjects: 155
Study 21947813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (all exercise groups combined)
Number of subjects: 155
Study 21947813 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 155
Study 21947813 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers with normal endothelial function (FMD ≥ 5.5%)
Number of subjects: 155
Study 20696980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent group (those who stayed on treatment)
Number of subjects: 3433
Study 20696980 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent group (those who discontinued treatment)
Number of subjects: 3433
Study 20696980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent group (after recalibration)
Number of subjects: 3433
Study 20696980 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of blood pressure monitoring
Number of subjects: 3433
Study 18230195 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alfa pen
Number of subjects: 171
Study 18230195 — intervention group
Group type: COMPARATOR
Intervention: Follitropin beta pen
Number of subjects: 171
Study 15813831 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 30
Study 15813831 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg twice daily
Number of subjects: 30
Study 12162112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exercise
Number of subjects: 26
Study 12162112 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 26
Study 9649990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 30
Study 9649990 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30
Study 7544175 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g resistant starch (100 g amylomaize starch)
Number of subjects: 7
Study 7544175 — intervention group
Group type: COMPARATOR
Intervention: Digestible starch
Number of subjects: 7
Study 7544175 — intervention group
Group type: COMPARATOR
Intervention: Resistant starch
Number of subjects: 7
Study 2671116 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg three times daily)
Number of subjects: 170
Study 2671116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 2671116 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 170
Study 795354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 0
Study 795354 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 0
Study 30699211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Number of subjects: 33
Study 30699211 — intervention group
Group type: COMPARATOR
Intervention: Free walking training
Number of subjects: 33
Study 28366450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced surgeons
Number of subjects: 70
Study 28366450 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 70
Study 26429655 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 2 mg/kg/d for six months
Number of subjects: 100
Study 26429655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 23954071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy (bupropion SR + nicotine lozenge, nicotine patch + nicotine lozenge)
Number of subjects: 1504
Study 23954071 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (bupropion SR, nicotine patch, nicotine lozenge)
Number of subjects: 1504
Study 23954071 — intervention group
Group type: COMPARATOR
Intervention: Cessation fatigue
Number of subjects: 1504
Study 22104033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% viscous lidocaine
Number of subjects: 100
Study 22104033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19588533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,210 nm laser exposure at fluences of 70, 80, and 90 J/cm(2)
Number of subjects: 24
Study 19588533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,210 nm laser exposure
Number of subjects: 24
Study 19588533 — intervention group
Group type: COMPARATOR
Intervention: Control sites (not exposed to laser)
Number of subjects: 24
Study 18164922 — intervention group
Group type: COMPARATOR
Intervention: Chronic Pain Sleep Inventory (CPSI) items measuring trouble falling asleep (CPSI1), awakened by pain during the night (CPSI3), and awakened by pain in the morning (CPSI4) on a 100-mm visual analog scale.
Number of subjects: 2674
Study 18164922 — intervention group
Group type: COMPARATOR
Intervention: CPSI items overall quality of sleep (CPSI5) on a 100-mm visual analog scale.
Number of subjects: 2674